Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-12-11
2007-12-11
Mondesi, Robert B. (Department: 1652)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
Reexamination Certificate
active
11226771
ABSTRACT:
The current invention relates to the field of hypoxia-induced disorders and more specifically to the use of hypoxia inducible factor 2α as a target in a method for the screening for molecules that can be used for the treatment of pulmonary hypertension. The invention further relates to the use of HIF-2α and/or of the HIF-2α inducible protein VEGF for the treatment of neonatal respiratory distress syndrome.
REFERENCES:
patent: 5695963 (1997-12-01), McKnight et al.
patent: 5840693 (1998-11-01), Eriksson et al.
patent: 6613563 (2003-09-01), Sosnowski et al.
Iassus et al., Vascular endothelial growth factor in human preterm lung, Am J Respir Crit Care Med., May 1999, vol. 159, pp. 1429-1433.
Acarregu et al., Vascular endothelial growth factor gene expression in human fetal lung in vitro, Am J Respir Cell Mol Biol., Jan. 1999, vol. 20, No. 1, pp. 14-23.
Maniscalco et al., Hyperoxic injury decreases alveolar epithelial cell expression of vascular endothelial growth factor (VEGF) in neonatal rabbit lung., Am J Respir Cell Mol Biol., May 1997, vol. 16, No. 5, pp. 557-567.
Jaakkola, et al. “Targeting of HIF-α to the von Hippell-Lindau Ubiquitylation Complex by O2-Regulated Prolyl Hydroxylation,”Science, vol. 292, pp. 468-472, Apr. 20, 2001.
Peng, et al. “The Transcription Factor EPAS-1/Hypoxia-Inducible Factor 2α Plays an Important Role in Vascular Remodeling,”Proceedings of the National Academy of Sciences, vol. 97, No. 15, pp. 8386-8391, Jul. 18, 2000.
Semenza, “HIF-1 and Human Disease: One Highly Involved Factor,”Genes&Development, vol. 14, pp. 1983-1991, 2000.
Tian, et al. “Endothelial PAS Domain Protein 1 (EPAS1), a Transcription Factor Selectively Expressed in Endothelial Cells,”Genes&Development, vol. 11, pp. 72-82, 1997.
International Search Report, issued Jul. 22, 2003.
Acarregui, et al. “Vascular Endothelial Growth Factor (VEGF) Induces Airway Epithelial Cell Proliferation and Surfactant Protein Gene Expression in Human Fetal Lung In Vitro,” Abstract from Annual Meeting of the American Pediatric Society and The Society for Pediatric Research held in New Orleans, LA, May 1-5, 1998, p. 44A.
Creuwels, et al. “The Pulmonary Surfactant System: Biochemical and Clinical Aspects,”Lungvol. 175, No. 1, pp. 1-39, 1997.
Ema, et al. “A Novel bHLH-PAS Factor with Close Sequence Similarity to Hypoxia-Inducible Factor 1-α Regulates the VEGF Expression and Its Potentially Involved in Lung and Vascular Development,”Proceedings of the National Academy of Sciences of USA, vol. 94, pp. 4273-4278, Apr. 1997.
European Search Report dated Mar. 15, 2007.
Carmeliet Peter
Compernolle Veerle
Knobbe Martens Olson & Bear LLP
Mondesi Robert B.
Vlaams Interuniversitair Instituut voor Biotechnologie VZW
LandOfFree
Hypoxia inducible factor 2α for curing neonatal... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Hypoxia inducible factor 2α for curing neonatal..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hypoxia inducible factor 2α for curing neonatal... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3870255